Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$3.0B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge how well GRAIL is managing its expenses relative to revenue this quarter.

$-2.45

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection tests.

$44M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. Operating in the health care sector, GRAIL's work is significant as it aims to improve patient outcomes by identifying cancers at earlier stages, which can lead to more effective treatments.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1-2026, GRAIL reported an EPS of $-2.29, which was better than the expected $-3.00, marking a positive surprise. However, revenue details were not disclosed, and the stock fell slightly the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss of $-2.45 per share with revenues around $44 million. The market is closely watching for any signs of improved sales or cost management.

Bull Case

If GRAIL can exceed revenue expectations and continue its trend of EPS surprises, it may signal strong demand for its products and effective cost control, which could boost investor confidence.

Bear Case

Conversely, if GRAIL fails to meet revenue expectations or reports wider losses, it could raise concerns about its business model and market viability, leading to a negative reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$-2.45

EPS is a key indicator of profitability and will help gauge how well GRAIL is managing its expenses relative to revenue this quarter.

Revenue

$44M

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection tests.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL's revenue meet or exceed the $44 million consensus?

Revenue performance will be crucial in assessing market demand for GRAIL's products and its overall financial health.

What specific strategies is GRAIL implementing to manage costs and improve EPS?

Understanding cost management strategies will provide insight into the company's path to profitability and long-term sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth given its recent positive EPS surprises, which indicate better-than-expected cost management.

Supporting Evidence

GRAIL has consistently surprised on EPS, suggesting that the consensus may be overly conservative.

The options market is pricing a larger move than historical averages, indicating heightened expectations for volatility.

Recent trends in the biotechnology sector show increased investment in early cancer detection, which could benefit GRAIL.

Key Risk

If revenue comes in below $42 million, it could undermine the positive narrative built around recent EPS surprises.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on GRAIL's ability to generate revenue and manage costs effectively, which are critical for its growth and investor confidence.

Bull Confirmed If

Revenue exceeding $44 million with a narrower EPS loss than $-2.45 would confirm the bull case.

Bear Confirmed If

Revenue falling below $42 million or an EPS loss wider than $-2.45 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by an average of +1.90% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around -2.26% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance product distribution.
2Details on customer acquisition strategies and market penetration efforts.
3Insights into R&D progress and upcoming product launches.
4Management's outlook on the competitive landscape in cancer detection.
5Any commentary on cost management strategies and their impact on future profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge how well GRAIL is managing its expenses relative to revenue this quarter.

$-2.45

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection tests.

$44M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss of $-2.45 per share with revenues around $44 million. The market is closely watching for any signs of improved sales or cost management.

Bull Case

If GRAIL can exceed revenue expectations and continue its trend of EPS surprises, it may signal strong demand for its products and effective cost control, which could boost investor confidence.

Bear Case

Conversely, if GRAIL fails to meet revenue expectations or reports wider losses, it could raise concerns about its business model and market viability, leading to a negative reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$-2.45

EPS is a key indicator of profitability and will help gauge how well GRAIL is managing its expenses relative to revenue this quarter.

Revenue

$44M

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection tests.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL's revenue meet or exceed the $44 million consensus?

Revenue performance will be crucial in assessing market demand for GRAIL's products and its overall financial health.

What specific strategies is GRAIL implementing to manage costs and improve EPS?

Understanding cost management strategies will provide insight into the company's path to profitability and long-term sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth given its recent positive EPS surprises, which indicate better-than-expected cost management.

Supporting Evidence

GRAIL has consistently surprised on EPS, suggesting that the consensus may be overly conservative.

The options market is pricing a larger move than historical averages, indicating heightened expectations for volatility.

Recent trends in the biotechnology sector show increased investment in early cancer detection, which could benefit GRAIL.

Key Risk

If revenue comes in below $42 million, it could undermine the positive narrative built around recent EPS surprises.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on GRAIL's ability to generate revenue and manage costs effectively, which are critical for its growth and investor confidence.

Bull Confirmed If

Revenue exceeding $44 million with a narrower EPS loss than $-2.45 would confirm the bull case.

Bear Confirmed If

Revenue falling below $42 million or an EPS loss wider than $-2.45 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by an average of +1.90% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around -2.26% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance product distribution.
2Details on customer acquisition strategies and market penetration efforts.
3Insights into R&D progress and upcoming product launches.
4Management's outlook on the competitive landscape in cancer detection.
5Any commentary on cost management strategies and their impact on future profitability.